Oxytocin-augmented group psychotherapy for patients with schizophrenia spectrum disorders

SUMMARY
Negative symptoms (NS) in patients with schizophrenia spectrum disorder (SSD), such as reduced emotional expression and social withdrawal, remain a challenge and limit the efficacy of existing treatments. This project aims to develop and optimize a combination therapy of Mindfulness-Based Group Therapy and oxytocin administration (OXYMIND) to improve the overall well-being and quality of life for patients. We will perform an interventional study and investigate potential mechanism of action to improve therapeutic effects.

PROJECT GOALS
• Complete a randomized control trial evaluating OXYMIND for the treatment of NS in patients with SSD.
• Identify potential mechanism of action to optimize therapeutic effects.

LONG-TERM GOALS
• Establish OXYMIND as a validated and effective treatment option for NS in patients with SSD in different medical centers and countries.